See more : HWASHIN CO.,Ltd (010690.KS) Income Statement Analysis – Financial Results
Complete financial analysis of UCB SA (UCBJY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UCB SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Shenzhen Anche Technologies Co., Ltd. (300572.SZ) Income Statement Analysis – Financial Results
- Formosa Prosonic Industries Berhad (9172.KL) Income Statement Analysis – Financial Results
- Remedy Entertainment Oyj (REMEDY.HE) Income Statement Analysis – Financial Results
- Zhejiang Zhongxin Fluoride Materials Co.,Ltd (002915.SZ) Income Statement Analysis – Financial Results
- Grupo Aval Acciones y Valores S.A. (AVAL) Income Statement Analysis – Financial Results
UCB SA (UCBJY)
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.25B | 5.52B | 5.78B | 5.35B | 4.91B | 4.63B | 4.53B | 4.18B | 3.88B | 3.34B | 3.41B | 3.46B | 3.25B | 3.22B | 3.12B | 3.60B | 3.63B | 2.52B | 2.34B | 3.53B | 3.33B | 5.64B |
| Cost of Revenue | 1.71B | 1.68B | 1.44B | 1.36B | 1.27B | 1.20B | 1.20B | 1.20B | 1.16B | 1.05B | 1.11B | 1.08B | 1.01B | 1.05B | 1.03B | 1.15B | 1.05B | 541.00M | 550.00M | 927.86M | 929.96M | 2.46B |
| Gross Profit | 3.55B | 3.84B | 4.34B | 3.98B | 3.65B | 3.43B | 3.33B | 2.98B | 2.72B | 2.29B | 2.30B | 2.38B | 2.23B | 2.17B | 2.09B | 2.46B | 2.58B | 1.98B | 1.79B | 2.61B | 2.40B | 3.18B |
| Gross Profit Ratio | 67.50% | 69.64% | 75.11% | 74.51% | 74.19% | 74.14% | 73.51% | 71.23% | 70.15% | 68.51% | 67.34% | 68.69% | 68.79% | 67.28% | 67.11% | 68.18% | 71.13% | 78.56% | 76.51% | 73.75% | 72.05% | 56.37% |
| Research & Development | 1.63B | 1.67B | 1.63B | 1.57B | 1.27B | 1.16B | 1.06B | 1.02B | 1.04B | 928.00M | 856.00M | 890.00M | 780.00M | 705.00M | 674.00M | 767.00M | 788.00M | 615.00M | 511.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 230.00M | 225.00M | 208.00M | 196.00M | 195.00M | 180.00M | 192.00M | 184.00M | 192.00M | 201.00M | 205.00M | 198.00M | 193.00M | 194.00M | 189.00M | 228.00M | 267.00M | 196.00M | 230.00M | 736.63M | 712.31M | 604.13M |
| Selling & Marketing | 1.59B | 1.49B | 1.35B | 1.22B | 1.11B | 964.00M | 940.00M | 940.00M | 904.00M | 779.00M | 802.00M | 875.00M | 837.00M | 797.00M | 781.00M | 928.00M | 1.05B | 733.00M | 653.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 1.82B | 1.71B | 1.55B | 1.42B | 1.30B | 1.14B | 1.13B | 1.12B | 1.10B | 980.00M | 1.01B | 1.07B | 1.03B | 991.00M | 970.00M | 1.16B | 1.32B | 929.00M | 883.00M | 736.63M | 712.31M | 604.13M |
| Other Expenses | -513.00M | -243.00M | -166.00M | -102.00M | -3.00M | -59.00M | -22.00M | -46.00M | -79.00M | -41.00M | -23.00M | -7.00M | 13.00M | 2.00M | -589.00M | -13.00M | -33.00M | -159.00M | -34.00M | 1.39B | 1.20B | -911.49M |
| Operating Expenses | 2.94B | 3.14B | 3.02B | 2.88B | 2.57B | 2.27B | 2.19B | 2.01B | 2.00B | 1.88B | 1.81B | 1.93B | 1.82B | 1.70B | 1.06B | 1.91B | 2.08B | 1.39B | 1.36B | 2.12B | 1.91B | -307.37M |
| Cost & Expenses | 4.65B | 4.82B | 4.46B | 4.25B | 3.84B | 3.47B | 3.39B | 3.21B | 3.16B | 2.94B | 2.92B | 3.02B | 2.84B | 2.75B | 2.08B | 3.06B | 3.12B | 1.93B | 1.91B | 3.05B | 2.84B | 2.15B |
| Interest Income | 15.00M | 12.00M | 7.00M | 14.00M | 17.00M | 16.00M | 14.00M | 33.00M | 6.00M | 50.00M | 37.00M | 20.00M | 90.00M | 9.00M | 59.00M | 28.00M | 41.00M | 15.00M | 46.00M | 403.77M | 463.25M | 15.32M |
| Interest Expense | 144.00M | 71.00M | 45.00M | 68.00M | 60.00M | 62.00M | 56.00M | 87.00M | 86.00M | 145.00M | 160.00M | 144.00M | 205.00M | 194.00M | 221.00M | 184.00M | 166.00M | 69.00M | 48.00M | 404.77M | 0.00 | 24.09M |
| Depreciation & Amortization | 691.00M | 585.00M | 323.00M | 354.00M | 313.00M | 287.00M | 245.00M | 235.00M | 250.00M | 220.00M | 238.00M | 230.00M | 246.00M | 255.00M | 220.00M | 180.00M | 160.00M | 90.00M | 92.00M | 333.79M | 307.54M | 327.35M |
| EBITDA | 1.28B | 1.17B | 1.59B | 1.30B | 1.33B | 1.40B | 1.31B | 1.03B | 762.00M | 600.00M | 544.00M | 637.00M | 614.00M | 468.00M | 1.12B | 321.00M | 545.00M | 678.00M | 502.00M | 355.00M | 797.61M | 829.75M |
| EBITDA Ratio | 24.30% | 23.07% | 26.88% | 26.35% | 27.21% | 30.20% | 28.81% | 26.97% | 22.99% | 17.70% | 21.87% | 17.97% | 22.98% | 22.72% | 42.20% | 20.91% | 19.42% | 27.82% | 25.20% | 23.47% | 23.97% | 16.73% |
| Operating Income | 604.00M | 585.00M | 1.28B | 971.00M | 1.07B | 1.11B | 1.09B | 876.00M | 522.00M | 273.00M | 403.00M | 389.00M | 344.00M | 204.00M | 837.00M | 113.00M | 344.00M | 571.00M | 364.00M | 484.01M | 486.54M | 502.40M |
| Operating Income Ratio | 11.50% | 10.60% | 22.23% | 18.16% | 21.74% | 23.94% | 24.00% | 20.97% | 13.47% | 8.16% | 11.81% | 11.24% | 10.60% | 6.34% | 26.86% | 3.14% | 9.49% | 22.63% | 15.55% | 13.70% | 14.62% | 8.91% |
| Total Other Income/Expenses | -163.00M | -74.00M | -58.00M | -91.00M | -108.00M | -94.00M | -99.00M | -112.00M | -96.00M | -162.00M | -142.00M | -155.00M | -115.00M | -185.00M | -162.00M | -156.00M | -125.00M | -54.00M | -2.00M | 8.33M | -7.33M | -36.02M |
| Income Before Tax | 441.00M | 511.00M | 1.23B | 880.00M | 960.00M | 1.02B | 988.00M | 764.00M | 426.00M | 111.00M | 282.00M | 242.00M | 229.00M | 19.00M | 675.00M | -43.00M | 219.00M | 517.00M | 362.00M | 492.34M | 479.21M | 466.38M |
| Income Before Tax Ratio | 8.40% | 9.26% | 21.22% | 16.46% | 19.54% | 21.91% | 21.81% | 18.29% | 10.99% | 3.32% | 8.27% | 6.99% | 7.05% | 0.59% | 21.66% | -1.19% | 6.04% | 20.49% | 15.46% | 13.93% | 14.40% | 8.27% |
| Income Tax Expense | 98.00M | 91.00M | 170.00M | 119.00M | 146.00M | 200.00M | 218.00M | 199.00M | 111.00M | 6.00M | 87.00M | 7.00M | 8.00M | -86.00M | 168.00M | -30.00M | 60.00M | 150.00M | 92.00M | 129.46M | 140.20M | 136.31M |
| Net Income | 343.00M | 418.00M | 1.06B | 732.00M | 792.00M | 800.00M | 753.00M | 520.00M | 623.00M | 209.00M | 207.00M | 256.00M | 235.00M | 104.00M | 514.00M | 43.00M | 161.00M | 367.00M | 755.00M | 363.04M | 339.68M | 331.81M |
| Net Income Ratio | 6.53% | 7.58% | 18.31% | 13.69% | 16.12% | 17.27% | 16.62% | 12.45% | 16.07% | 6.25% | 6.07% | 7.39% | 7.24% | 3.23% | 16.50% | 1.19% | 4.44% | 14.55% | 32.25% | 10.27% | 10.21% | 5.88% |
| EPS | 1.76 | 2.20 | 5.60 | 3.87 | 4.23 | 4.24 | 4.00 | 2.76 | 3.24 | 1.10 | 1.14 | 1.43 | 1.32 | 0.58 | 2.85 | 0.24 | 0.89 | 2.54 | 5.26 | 2.51 | 2.33 | 1.84 |
| EPS Diluted | 1.76 | 2.15 | 5.45 | 3.77 | 4.23 | 4.24 | 4.00 | 2.76 | 3.24 | 1.10 | 1.07 | 1.43 | 1.23 | 0.56 | 2.76 | 0.24 | 0.88 | 2.48 | 5.17 | 2.49 | 2.33 | 1.82 |
| Weighted Avg Shares Out | 194.89M | 189.62M | 188.97M | 189.04M | 187.22M | 188.48M | 188.28M | 188.37M | 192.08M | 190.46M | 182.16M | 179.28M | 178.49M | 180.15M | 180.18M | 180.17M | 180.17M | 144.38M | 143.51M | 144.45M | 145.93M | 180.17M |
| Weighted Avg Shares Out (Dil) | 195.19M | 194.83M | 194.18M | 194.25M | 187.22M | 188.48M | 188.28M | 188.37M | 192.08M | 190.46M | 193.26M | 179.34M | 191.51M | 184.20M | 186.43M | 182.59M | 183.37M | 147.74M | 146.12M | 145.93M | 145.93M | 182.59M |
Source: https://incomestatements.info
Category: Stock Reports